188 related articles for article (PubMed ID: 19375649)
21. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
[TBL] [Abstract][Full Text] [Related]
22. Amyloid precursor protein cooperates with c-KIT mutation/overexpression to regulate cell apoptosis in AML1-ETO-positive leukemia via the PI3K/AKT signaling pathway.
Yu G; Yin C; Jiang L; Zheng Z; Wang Z; Wang C; Zhou H; Jiang X; Liu Q; Meng F
Oncol Rep; 2016 Sep; 36(3):1626-32. PubMed ID: 27460334
[TBL] [Abstract][Full Text] [Related]
23. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.
Bibi S; Arslanhan MD; Langenfeld F; Jeanningros S; Cerny-Reiterer S; Hadzijusufovic E; Tchertanov L; Moriggl R; Valent P; Arock M
Haematologica; 2014 Mar; 99(3):417-29. PubMed ID: 24598853
[TBL] [Abstract][Full Text] [Related]
24. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
25. Lnk constrains myeloproliferative diseases in mice.
Bersenev A; Wu C; Balcerek J; Jing J; Kundu M; Blobel GA; Chikwava KR; Tong W
J Clin Invest; 2010 Jun; 120(6):2058-69. PubMed ID: 20458146
[TBL] [Abstract][Full Text] [Related]
26. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders.
Gery S; Gueller S; Chumakova K; Kawamata N; Liu L; Koeffler HP
Blood; 2007 Nov; 110(9):3360-4. PubMed ID: 17693582
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of Lnk in the Ovaries Is Involved in Insulin Resistance in Women With Polycystic Ovary Syndrome.
Hao M; Yuan F; Jin C; Zhou Z; Cao Q; Xu L; Wang G; Huang H; Yang D; Xie M; Zhao X
Endocrinology; 2016 Oct; 157(10):3709-3718. PubMed ID: 27459314
[TBL] [Abstract][Full Text] [Related]
28. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
[TBL] [Abstract][Full Text] [Related]
29. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Gishizky ML; Cortez D; Pendergast AM
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
[TBL] [Abstract][Full Text] [Related]
30. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
[TBL] [Abstract][Full Text] [Related]
31. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells.
Ning ZQ; Li J; Arceci RJ
Blood; 2001 Jun; 97(11):3559-67. PubMed ID: 11369651
[TBL] [Abstract][Full Text] [Related]
32. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
33. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.
Ren SY; Bolton E; Mohi MG; Morrione A; Neel BG; Skorski T
Mol Cell Biol; 2005 Sep; 25(18):8001-8. PubMed ID: 16135792
[TBL] [Abstract][Full Text] [Related]
34. Jak2 is involved in c-Myc induction by Bcr-Abl.
Xie S; Lin H; Sun T; Arlinghaus RB
Oncogene; 2002 Oct; 21(47):7137-46. PubMed ID: 12370803
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
36. G-protein coupled receptor 34 activates Erk and phosphatidylinositol 3-kinase/Akt pathways and functions as alternative pathway to mediate p185Bcr-Abl-induced transformation and leukemogenesis.
Zuo B; Li M; Liu Y; Li K; Ma S; Cui M; Qin Y; Zhu H; Pan X; Guo J; Dai Z; Yu W
Leuk Lymphoma; 2015 Jul; 56(7):2170-81. PubMed ID: 25363403
[TBL] [Abstract][Full Text] [Related]
37. The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
Maslah N; Cassinat B; Verger E; Kiladjian JJ; Velazquez L
Leukemia; 2017 Aug; 31(8):1661-1670. PubMed ID: 28484264
[TBL] [Abstract][Full Text] [Related]
38. LNK (SH2B3): paradoxical effects in ovarian cancer.
Ding LW; Sun QY; Lin DC; Chien W; Hattori N; Dong XM; Gery S; Garg M; Doan NB; Said JW; Xiao JF; Yang H; Liu LZ; Meng X; Huang RY; Tang K; Koeffler HP
Oncogene; 2015 Mar; 34(11):1463-74. PubMed ID: 24704825
[TBL] [Abstract][Full Text] [Related]
39. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
[TBL] [Abstract][Full Text] [Related]
40. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
Kharas MG; Janes MR; Scarfone VM; Lilly MB; Knight ZA; Shokat KM; Fruman DA
J Clin Invest; 2008 Sep; 118(9):3038-50. PubMed ID: 18704194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]